Gore Partners with Medinol on the Rebound in Global Stent Deal

WL Gore & Associates and Tel Aviv, Israel-based Medinol, both privately-held companies, enetered into a worldwide partnership agreement covering stents and stent systems, the exact terms of which have not been disclosed. What's clear, however, is that the deal enables each company to fill a significant hole in their interventional cardiology product lines, while also restoring worldwide distribution channels for Medinol. The Israeli company, which focuses exclusively on developing and manufacturing innovative stent technology, lost its sales and marketing channel this year after dissolving a longstanding agreement with Boston Scientific. Now, it will be able to utilize the balloon and stent delivery system that Gore plans on unveiling later this year, along with Gore's distribution network, while Gore will have access to Medinol's ionnovative stent line, including the new NIRflex stent.

As the stent market matures, how much value exists in having a balloon and a delivery system but not a stent? And similarly, how valuable is innovative stent technology without significant distribution capability? In both cases, the answer is apparently not enough in the views of W.L Gore & Associates Inc. and Tel Aviv, Israel-based Medinol Ltd. The two privately -held companies entered into a worldwide partnership agreement covering stents and stent systems, the exact terms of which have not been disclosed. [See Deal]. What's clear, however, is that the deal enables each company to fill a significant hole in their interventional cardiology product lines, while also restoring worldwide distribution channels for Medinol. The Israeli company, which focuses exclusively on developing and manufacturing innovative stent technology, lost its sales and marketing channel this year after dissolving a longstanding agreement with Boston Scientific Corp. Now, it will be able to utilize the balloon and stent delivery system that Gore plans on unveiling later this year, along with Gore's distribution network, while Gore will have access to Medinol's innovative stent line, including the new NIRflex stent.

Medinol had been Boston Scientific's exclusive stent supplier since the two companies signed a ten-year worldwide distribution agreement in 1995....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Innovation

In Conversation With Foundation Fighting Blindness

 
• By 

Jason Menzo, CEO of the Foundation Fighting Blindness, says the organization is adapting its funding strategy, navigating regulatory challenges and accelerating the translation of academic discoveries into industry-led clinical development.

Mapping Biopharma’s AI Strategy: From Custom Datasets to Foundation Models

 
• By 

Biotech companies are pursuing diverse AI strategies beyond expensive custom data generation: foundation model fine-tuning, data-efficient computational methods and targeted proprietary datasets. In Vivo takes a look at some examples.

This Belgian Biotech’s Drug Cocktail Could Help Reverse Muscle Aging

 
• By 

While big pharma pours billions into creating new anti-aging molecules, a Belgian startup has taken a different path: combining existing safe drugs with AI precision. The early results suggest it might be onto something revolutionary.

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

More from In Vivo

Wide Of The Mark: ‘The Worst EU Medtech Predictions Have Not Come True’

 
• By 

Jana Grieb, European regulatory and market access legal expert at McDermott Will & Emery, explains why the healthtech and pharma industries are warming to the new EU health commissioner as he faces calls to make the MDR more “user friendly.”

This Belgian Biotech’s Drug Cocktail Could Help Reverse Muscle Aging

 
• By 

While big pharma pours billions into creating new anti-aging molecules, a Belgian startup has taken a different path: combining existing safe drugs with AI precision. The early results suggest it might be onto something revolutionary.

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By 

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy